All Type of News
Ilyang Pharm’s ‘Prion Treatment Development’ selection as study supported by MOHW
The Ilyang Pharm’s(CEO Dong-Yeon Kim) development of prion treatment has recently been selected as the ‘Development of Technology to Overcome Diseases Transmitted Cross-species to Humans’ by the Ministry of Health and...
Daewoong Pharmaceutical’s Ursa challenges U.S. market with new look
‘Ursa’ will have a new look in 58 years of its launch. Daewoong Pharmaceutical is currently taking a new direction to renew the product which has grown 20% up in sales for the past 3 years.
With the uptrend, it is al...
Siemens Healthineers, “We’ll file a suit because the FTC’s decision infringed intellectual properties.”
Siemens Healthineers Korea(CEO/President Myung-Gyun Lee) announced that not only was the result of discussion the Fair Trade Commission(FTC) announced about the Siemens’ misuse of superiority in market on the 17th not...
Yuhan Corporation Jung-Hee Lee internally nominated as next Chair
Yuhan Corporation CEO Jung-Hee Lee was nominated as the next Chair of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA). Ever since Chair Heng-Myung Lee refused to continue the position with a w...
GC Pharma getting closer to world’s first commercialized recombinant protein for hepatitis B
GC Pharma(CEO Eun-Cheol Huh), formally known as Green Cross, announced on the 18th that the Phase II/III clinical trial plan for ‘GC1102(Hepabig-gene),’ a recombinant immunoglobulin for the treatment of hepatitis B, h...
Medtronic appoints President Hee-Yeol Lee as Asia-Pacific Head
Medtronic appointed President Hee-Yeol Lee(English name: Chris Lee) as Asia-Pacific Business Head.
In Singapore where its Asia-Pacific headquarters are located, President Hee-Yeol Lee will generally manage the busine...
Huons targets global eye drop market with extensive enlargement of manufacturing facilities
A subsidiary of Huons Global, Huons(CEO Gi-Ahn Um) will extensively enlarge manufacturing lines at its factory in Jecheon, Chungbuk to target the global eye drop market.
According to Huons, the company has decided to...
Alteogen’s ‘similarity’ for Eylea biosimilar with the original medicine
Alteogen(CEO Soon-Jae Park), an antibody biosimilar company, announced the company has secured ‘similarity’ for the Eylea biosimilar(ALT-L9) with the original medicine at a U.S. nonclinical trial and ended it without ...
Current status in clinical trial hospitals
With advancement of the Korean clinical trial industry and scientific technology, most hospitals designated for clinical trials are reportedly following examination and approval processes based on electronic systems, ...
Pharma industry having a hard time due to tyranny of CSOs
It was told pharmaceutical companies are reportedly having a hard time from the tyranny of some CSOs(Contract Sales Organizations).
According to the pharmaceutical industry, the number of CSOs selling medicines on be...
